GlassScriptPhysician profile
Roji Menon
NPI 1639269046
$2,652.13
in general payments reported to CMS, 2019-2025
29 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $196 · 2021: $540 · 2022: $584 · 2023: $573 · 2024: $154 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $451.12 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $340.73 | 2019-2022 | |
| Lilly USA, LLC | $327.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.72 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $196.26 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $119.51 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $114.48 | 2019-2025 | |
| Pfizer INC. | $105.05 | 2021-2025 | |
| Sanofi Pasteur INC. | $81.35 | 2019-2023 | |
| Exact Sciences Corporation | $81.08 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $79.44 | 2021-2023 | Proclaim |
| Mylan Specialty L.P. | $78.36 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $70.46 | 2020-2021 | |
| Daiichi Sankyo INC. | $49.85 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $37.98 | 2023 | Opsumit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.62 | 2025 | Repatha |
| Astellas Pharma US INC | $33.87 | 2021-2025 | Veozah |
| Gilead Sciences, INC. | $30.89 | 2021 | |
| Seqirus USA INC | $21.33 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Biohaven Pharmaceutical Holding Company LTD. | $20.23 | 2022 | |
| Amarin Pharma, INC. | $20.12 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.34 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.22 | 2021 | |
| Phadia US INC. | $17.28 | 2024 | Immunocap |
| Ibsa Pharma INC. | $15.76 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.98 | 2023 | Xarelto |
| Bardy Diagnostics, INC. | $14.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roji Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.